- Home
- NBIS vs PBMWW Comparison
NBIS vs PBMWW Comparison
Compare NBIS & PBMWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIS
- PBMWW
- Stock Information
- Founded
- NBIS 2000
- PBMWW N/A
- Country
- NBIS Netherlands
- PBMWW Canada
- Employees
- NBIS N/A
- PBMWW 10
- Industry
- NBIS
- PBMWW
- Sector
- NBIS
- PBMWW
- Exchange
- NBIS NYSE
- PBMWW Nasdaq
- Market Cap
- NBIS 5.5B
- PBMWW N/A
- IPO Year
- NBIS 2011
- PBMWW N/A
- Fundamental
- Price
- NBIS $36.89
- PBMWW $0.02
- Analyst Decision
- NBIS Strong Buy
- PBMWW
- Analyst Count
- NBIS 1
- PBMWW 0
- Target Price
- NBIS $51.00
- PBMWW N/A
- AVG Volume (30 Days)
- NBIS 6.1M
- PBMWW N/A
- Earning Date
- NBIS 02-12-2025
- PBMWW N/A
- Dividend Yield
- NBIS N/A
- PBMWW N/A
- EPS Growth
- NBIS N/A
- PBMWW N/A
- EPS
- NBIS N/A
- PBMWW N/A
- Revenue
- NBIS $8,657,142,250.00
- PBMWW N/A
- Revenue This Year
- NBIS N/A
- PBMWW N/A
- Revenue Next Year
- NBIS N/A
- PBMWW N/A
- P/E Ratio
- NBIS $35.21
- PBMWW N/A
- Revenue Growth
- NBIS 18.28
- PBMWW N/A
- 52 Week Low
- NBIS $14.09
- PBMWW N/A
- 52 Week High
- NBIS $38.69
- PBMWW N/A
- Technical
- Relative Strength Index (RSI)
- NBIS N/A
- PBMWW N/A
- Support Level
- NBIS N/A
- PBMWW N/A
- Resistance Level
- NBIS N/A
- PBMWW N/A
- Average True Range (ATR)
- NBIS 0.00
- PBMWW 0.00
- MACD
- NBIS 0.00
- PBMWW 0.00
- Stochastic Oscillator
- NBIS 0.00
- PBMWW 0.00
About NBIS NEBIUS GROUP N V
Nebius Group NV is a tech company. It is a European provider of infrastructure and services to AI builders globally. The group builds full-stack infrastructure to service the growth of the AI industry, including the scale of GPU clusters, cloud platforms, tools, and services for developers. It has R&D hubs across Europe, North America and Israel.
About PBMWW Psyence Biomedical Ltd. Warrant
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.